Using observational data to emulate a randomized trial of dynamic treatment switching strategies by Cain, Lauren E. et al.
Methodological insights
Using observational data to emulate a
randomized trial of dynamic treatment-
switching strategies: an application to
antiretroviral therapy
Writing committee: Lauren E Cain,1* Michael S Saag,2 Maya Petersen,3
Margaret T May,4 Suzanne M Ingle,4 Roger Logan,1 James M Robins,1,5
Sophie Abgrall,6,7 Bryan E Shepherd,8 Steven G Deeks,9 M John Gill,10
Giota Touloumi,11 Georgia Vourli,11 Franc¸ois Dabis,12
Marie-Anne Vandenhende,12 Peter Reiss,13,14 Ard van Sighem,13
Hasina Samji,15 Robert S Hogg,15,16 Jan Rybniker,17 Caroline A Sabin,18
Sophie Jose,18 Julia del Amo,19,20 Santiago Moreno,21,22
Benigno Rodrı´guez,23 Alessandro Cozzi-Lepri,24 Stephen L Boswell,25
Christoph Stephan,26 Santiago Pe´rez-Hoyos,27 Inma Jarrin,19,20
Jodie L Guest,28,29,30 Antonella D’Arminio Monforte,31 Andrea Antinori,32
Richard Moore,33 Colin NJ Campbell,20,34 Jordi Casabona,20,34,35
Laurence Meyer,36 Re´monie Seng,36 Andrew N Phillips,18
Heiner C Bucher,37 Matthias Egger,38,39 Michael J Mugavero,40
Richard Haubrich,41 Elvin H Geng,42 Ashley Olson,43 Joseph J Eron,44
Sonia Napravnik,44 Mari M Kitahata,45 Stephen E Van Rompaey,45
Ramo´n Teira,46 Amy C Justice,47,48 Janet P Tate,47,48
Dominique Costagliola,49 Jonathan AC Sterne,4 and
Miguel A Herna´n1,5,50 on behalf of the Antiretroviral Therapy Cohort
Collaboration, the Centers for AIDS Research Network of Integrated
Clinical Systems, and the HIV-CAUSAL Collaboration
1Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA, 2Department
of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA, 3Divisions of Biostatistics and
Epidemiology, University of California, Berkeley, School of Public Health, Berkeley, CA, USA, 4School of
Social and Community Medicine, University of Bristol, Bristol, UK, 5Department of Biostatistics, Harvard
T.H. Chan School of Public Health, Boston, MA, USA, 6Sorbonne Universite´s, UPMC Univ Paris 06, INSERM,
Institut Pierre Louis d’e´pide´miologie et de Sante´ Publique (IPLESP UMRS 1136), F75013, Paris, France,
7Assistance Publique-Hoˆpitaux de Paris (AP-HP), Hoˆpital Antoine Be´cle`re, Service de Me´decine Interne,
Clamart, France, 8Department of Biostatistics, Vanderbilt University School of Medicine, Nashville,
Tennessee, USA, 9Positive Health Program, San Francisco General Hospital, San Francisco, CA, USA,
10Division of Infectious Diseases, University of Calgary, Calgary, AB, Canada, 11Department of Hygiene,
Epidemiology and Medical Statistics, Athens University Medical School, Athens, Greece, 12INSERM U897,
Centre Inserm Epide´miologie et Biostatistique, Universite´ de Bordeaux, and Bordeaux University Hospital,
VC The Author 2015; all rights reserved. Published by Oxford University Press on behalf of the International Epidemiological Association 2038
International Journal of Epidemiology, 2016, 2038–2049
doi: 10.1093/ije/dyv295
Advance Access Publication Date: 31 December 2015
Original article
Department of Internal Medicine, Bordeaux, France, 13Stichting HIV Monitoring, Amsterdam, Netherlands,
14Academic Medical Center, Department of Global Health and Division of Infectious Diseases, University of
Amsterdam, and Amsterdam Institute for Global Health and Development, Amsterdam, Netherlands,
15Epidemiology and Population Health Program, BC Centre for Excellence in HIV/AIDS, Vancouver, BC,
Canada, 16Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada, 171st Department of
Internal Medicine, University of Cologne, D-50937 Cologne, Germany, 18University College London, London,
UK, 19National Centre of Epidemiology, Instituto de Salud Carlos III, Madrid, Spain, 20Consorcio de
Investigacio´n Biome´dica de Epidemiologı´a y Salud Pu´blica (CIBERESP), Madrid, Spain, 21Ramo´n y Cajal
Hospital, IRYCIS, Madrid, Spain, 22University of Alcala´ de Henares, Madrid, Spain, 23Division of Infectious
Disease, Case Western Reserve University, Cleveland, OH, USA, 24Department of Infection and Population
Health; Division of Population Health, University College London, London, UK, 25Fenway Health, Boston,
MA, USA, 26HIV Center, Department of Infectious Diseases, University Hospital, Frankfurt, Germany, 27Vall
d’Hebron Research Institute, Barcelona, Spain, 28Rollins School of Public Health at Emory University,
Atlanta, GA, USA, 29Emory University School of Medicine, Atlanta, GA, USA, 30Atlanta Veterans Affairs
Medical Center, Decatur, GA, USA, 31Clinic of Infectious Diseases and Tropical Medicine, Department of
Health Sciences, San Paolo Hospital, University of Milan, Milan, Italy, 32Istituto Nazionale per le Malattie
Infettive Lazzaro Spallanzani IRCCS, Rome, Italy, 33School of Medicine, Johns Hopkins University,
Baltimore, MD, USA, 34Center for Epidemiological Studies on HIV/AIDS and STI of Catalonia (CEEISCAT),
Age`ncia Salut Pu´blica de Catalunya (ASPC), Generalitat de Catalunya, Badalona, 08916 Catalonia, Spain,
35Department of Paediatrics, Obstetrics, Gynaecology and Preventive Medicine, Universitat Auto`noma de
Barcelona, Bellaterra, 08193 Catalonia, Spain, 36Universite´ Paris Sud, INSERM CESP U1018, and AP-HP,
Hoˆpital de Biceˆtre, Service de Sante´ Publique, le Kremlin Biceˆtre, France, 37Basel Institute for Clinical
Epidemiology and Biostatistics, University Hospital Basel, Basel, Switzerland, 38Centre for Infectious
Disease Epidemiology and Research, School of Public Health and Family Medicine, Faculty of Health
Sciences, University of Cape Town, Cape Town, South Africa, 39University of Bern, Institute for Social and
Preventive Medicine, Bern, Switzerland, 40University of Alabama at Birmingham, Birmingham, AL, USA,
41University of California San Diego, CA, USA (Currently Gilead Sciences, Foster City, CA, USA), 42Division
of HIV/AIDS, Department of Medicine, University of California, San Francisco, CA, USA, 43Medical
Research Council Clinical Trials Unit, University College London, London, UK, 44Division of Infectious
Diseases, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA,
45Department of Medicine, University of Washington, Seattle, WA, USA, 46Unit of Infectious Diseases,
Hospital Sierrallana, Torrelavega, Spain, 47Yale School of Medicine, New Haven, CT, USA, 48VA Connecticut
Healthcare System, West Haven, CT, USA, 49Sorbonne Universite´s, UPMC Univ Paris 06, INSERM, Institut
Pierre Louis d’e´pide´miologie et de Sante´ Publique (IPLESP UMRS 1136), F75013, Paris, France and
50Harvard-MIT Division of Health Sciences and Technology, Boston, MA, USA
*Corresponding author. Department of Epidemiology, Harvard T. H. Chan School of Public Health, 677 Huntington Avenue,
Boston MA 02115, USA. E-mail: lcain@hsph.harvard.edu
Accepted 5 October 2015
Abstract
Background: When a clinical treatment fails or shows suboptimal results, the question
of when to switch to another treatment arises. Treatment switching strategies are
often dynamic because the time of switching depends on the evolution of an individual’s
time-varying covariates. Dynamic strategies can be directly compared in randomized
trials. For example, HIV-infected individuals receiving antiretroviral therapy could
be randomized to switching therapy within 90 days of HIV-1 RNA crossing above a
threshold of either 400 copies/ml (tight-control strategy) or 1000 copies/ml (loose-control
strategy).
Methods: We review an approach to emulate a randomized trial of dynamic switching
strategies using observational data from the Antiretroviral Therapy Cohort Collaboration,
the Centers for AIDS Research Network of Integrated Clinical Systems and the
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HIV-CAUSAL Collaboration. We estimated the comparative effect of tight-control vs.
loose-control strategies on death and AIDS or death via inverse-probability weighting.
Results: Of 43 803 individuals who initiated an eligible antiretroviral therapy regimen in
2002 or later, 2001 met the baseline inclusion criteria for the mortality analysis and 1641
for the AIDS or death analysis. There were 21 deaths and 33 AIDS or death events in the
tight-control group, and 28 deaths and 41 AIDS or death events in the loose-control
group. Compared with tight control, the adjusted hazard ratios (95% confidence interval)
for loose control were 1.10 (0.73, 1.66) for death, and 1.04 (0.86, 1.27) for AIDS or death.
Conclusions: Although our effective sample sizes were small and our estimates imprecise,
the described methodological approach can serve as an example for future analyses.
Key words: HIV, antiretroviral therapy, inverse-probability weighting, observational studies, mortality, dynamic
strategies
Introduction
Many clinical decisions involve switching or discontinuing
treatment. The most effective switching strategies are
dynamic, that is, they involve switching different individuals
at different times depending on the evolution of their time-
varying covariates. However, very few randomized trials com-
pare dynamic strategies for switching treatments. Despite this
lack of clinical evidence, many clinical guidelines provide rec-
ommendations in the form of dynamic switching strategies.
For example, the guidelines for the management of HIV-
infected patients issued by the United States Department of
Health and Human Services (DHHS)1 and the International
AIDS Society-USA Panel2 recommend switching a patient’s
antiretroviral regimen immediately after a confirmed virolog-
ical failure (i.e. two consecutive HIV-1 RNA measure-
ments200 copies/ml). The European AIDS Clinical
Society3 and British HIV Association4 guidelines recommend
switching immediately if HIV-1 RNA> 500 copies/ml
or> 400 copies/ml, respectively, but suggest repeating a viral
load measurement if HIV-1 RNA is detected below the
threshold for switching. The World Health Organization5
guidelines recommend waiting to switch until confirmation
of HIV-1 RNA> 1000 copies/ml, the lowest level that can
be used when measuring viral load from dried blood spots.
Generally, the harder to implement tight-control strategies
are recommended to avoid the use of failing antiretrovirals
in the presence of ongoing viral replication which may lead
to drug-resistant mutations, use of more expensive drugs and
limitations on future treatment options.6–9
Here we review a framework for the comparison of
dynamic switching strategies using observational data.10–14
We begin by describing the protocol of the hypothetical
randomized trial we would like to conduct (the target
trial). We then review an approach to emulate this target
trial using observational data. To overcome the limitations
of standard methods for adjustment for time-varying
confounders,15,16 we use inverse-probability weighting of a
dynamic marginal structural model.17
The protocol of the target trial
The target trial is a hypothetical randomized trial that is speci-
fied in order to guide our analysis of observational data. Key
components of its design are eligibility criteria, treatment
strategies being compared, follow-up period, outcomes, causal
contrasts of interest and analysis plan. Discussions between
colleagues with clinical and statistical backgrounds are gener-
ally needed to specify a target trial whose results would be
most useful to resolve uncertainties in clinical practice. We de-
scribe the components of the target trial below.
Key Messages
• A randomized trial comparing dynamic treatment-switching strategies can be emulated by applying inverse-
probability weighting of a dynamic marginal structural model to observational data.
• This approach is facilitated by specifying the protocol of the target trial one would like to emulate in terms of the eli-
gibility criteria, the treatment strategies, the follow-up period, outcomes, causal contrasts and analysis plan.
• This approach detected little or no differences between switching at HIV-1 RNA thresholds of 400 and 1000 copies/ml in
preventing death and AIDS-defining illness.
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Eligibility criteria
The trial includes individuals who initiated antiretroviral ther-
apy in 2002 or later, achieved suppression of viral replication
(defined as at least one measurement of HIV-1 RNA 200
copies/ml) within 360 days of initiating treatment, and
then experienced confirmed virological failure (defined as the
second of two measurements of HIV-1 RNA>200 copies/ml
7–180 days apart). At confirmed virological failure (baseline),
individuals are required to be 18 years of age or older and to
have had a CD4 cell count measurement in the previous 90
days. Eligible antiretroviral regimens before first virological
failure are listed in Table 1.
Treatment strategies
Eligible individuals are randomized to either tight- or loose-
control strategies at confirmed virological failure. The tight-
control strategy is ‘switch within 90 days of HIV-1 RNA
crossing above 400 copies/ml’. The loose-control strategy is
‘switch within 90 days of HIV-1 RNA crossing above 1000
copies/ml’. In both arms, individuals should switch from regi-
mens at baseline to new regimens (as indicated in Table 2)
and switches are expected to occur uniformly11 during the 90-
day grace period. After the initial switch, individuals may sub-
sequently switch to another regimen or discontinue treatment
if clinically indicated or recommended by their treating
Table 1. Eligible initial regimens
Regimen classification Eligible initial regimensa
PIþ2 NRTI All regimens where the PI is either fosamprenavir (FAPV) or atazanavir (ATV) except those containing the
NRTI tenofovir (TNV) or an excluded drugb
bPIþ2 NRTI All regimens except those containing an excluded drugb
NNRTIþ2 NRTI All regimens except those containing an excluded drugb
< 6 drugs including
FI/INSTI (þ entry inhibitors)
All drug regimens with  3 drugs except those containing an excluded drugb
PI, protease inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; bPI, boosted protease inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor;
FI, fusion inhibitor; INSTI, integrase strand transfer inhibitor.
aEligible regimens were determined by a panel of clinicians on the basis of treatment guidelines.
bThe following drugs are excluded from initial regimens: enfuvirtide (ENF), zalcitabine (DDC), tipranavir (TPV), alovudine (ALO), capravirine (CPV), DPC
083 (DPC083), delavirdine (DLV), emivirine (EMV), lodenosine (DDA or LDN), loviride (LOV), mozenavir (MOZ), vicriviroc (VIC) and any unspecified drugs
(ART, PI, NNRTI, NRTI).
Table 2. Changes from initial regimens to new regimens that are considered switchesa
Regimen
classification
Switch from
(PIþ2 NRTI)?
Switch from
(bPIþ2 NRTI)?
Switch from
(NNRTIþ2 NRTI)?
Switch from (< 6 drugs
including FI/INSTIþ (entry
inhibitors))?
PIþ2 NRTI Nob No Yes Yes
bPIþ2 NRTI Yes Yes if PI changesb Yes Yes
NNRTIþ2 NRTI Yes Yes Yes if NNRTI to etravirine
(ETV)b
Yes
bPIþPI/NNRTI (þ
other)
Yes Yes Yes if NNRTI to etravirine
(ETV)b
Yes
< 6 drugs including
FI/INSTI (þ entry
inhibitors)
Yes Yes Yes Yes if FI/II/entry inhibitor
changes or addition of a
FI/II/entry inhibitorb
If the cell reads ‘no’, this type of change is never considered a switch. Changes to regimen classifications other than those in the table are never switches. If the
cell reads ‘yes’, this type of change is always considered a switch. If the cell reads ‘yes if . . . ’, the condition(s) listed must be met for the change to be considered a
switch. Other aspects of the regimen may also change or stay the same.
Individuals must change to regimens that do not include any of the following drugs: zalcitabine (DDC), alovudine (ALO), capravirine (CPV), DPC 083
(DPC083), delavirdine (DLV), emivirine (EMV), lodenosine (DDA or LDN), loviride (LOV), mozenavir (MOZ), vicriviroc (VIC) or any unspecified drugs (ART,
PI, NNRTI, NRTI).
PI, protease inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; bPI, boosted protease inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor;
FI, fusion inhibitor; INSTI, integrase strand transfer inhibitor.
aEligible regimens were determined by a panel of clinicians on the basis of treatment guidelines.
bOur primary definition of switching above does not include NRTI-only changes. An alternative definition includes some NRTI-only changes (i.e. any NRTI to
tenofovir (TNV) and tenofovir (TNV) to zidovudine (AZT)). According to this alternative definition, a change where the regimen classification does not change is
considered a switch if any part of the regimen changes (according to the conditions above).
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physicians. All individuals should be seen and have their CD4
cell count/HIV-1 RNA measured on average every 12–16
weeks and at least once every 52 weeks. As in all randomized
trials, we expect that some individuals will not adhere to the
target trial protocol.
Outcomes
The clinical outcomes of interest are all-cause mortality and
a combined endpoint of AIDS-defining illness18 or death.
Follow-up period
Individuals are followed from baseline (randomization) until
the outcome, loss to follow-up (52 weeks after the most
recent laboratory measurement) or the administrative end of
follow-up (3 years after baseline), whichever occurred first.
Causal contrasts of interest
To compare the two switching strategies, we estimate the
intention-to-treat effect and the per-protocol effect (i.e. the
effect that would have been observed if all participants had
switched as indicated in this protocol, regardless of the
treatment they received subsequently).
Analysis plan
Intention-to-treat analysis: We estimate 3-year Kaplan-
Meier survival curves by randomization arm. Despite its
limitations as an effect measure,19 we also estimate the mor-
tality hazard ratio via the pooled logistic model
logit Pr Dtþ1 ¼ 1 j Dt ¼ 0; Xð Þ ¼ b0t þ b1X, where Dt is
an indicator (1: yes, 0: no) for death in week t, b0t is a time-
specific intercept (the baseline hazard, estimated via linear
and quadratic terms for t), X is an indicator for randomiza-
tion arm (1: loose-control, 0: tight-control) and b1 is the log
odds ratio of mortality for loose vs tight control. Because
mortality is rare in each time interval, the parameter b1
approximates the log of the intention-to-treat mortality haz-
ard ratio that would have been estimated from a propor-
tional hazards Cox model.20 In case of a chance imbalance
of pre-treatment prognostic factors V between arms, the
model would include them as covariates.
Per-protocol analysis: Individuals are censored when
they deviate from their assigned switching strategy. In par-
ticular, individuals are censored at the time they change
treatment prematurely (i.e. between baseline and when
HIV-1 RNA first crosses above 400 copies/ml for tight
control and above 1000 for loose control), change to an in-
eligible regimen during the 90-day grace period and at the
end of the grace period if the individual has not yet
switched to an eligible regimen. Because this censoring
may be informative, adjustment for both baseline (pre-
randomization) and time-varying (post-randomization)
covariates may be necessary.11
To estimate a per-protocol mortality hazard ratio, we fit
a weighted model logit Pr Dtþ1 ¼ 1 j Dt ¼ 0;Ct ¼ 0;ð
X; VÞ ¼ h0t þ h1xþ h02V, where Ct is an indicator (1: yes,
0: no) for censoring due to deviating from the assigned
switching strategy in week t and V is a vector of the baseline
(time-fixed) covariates: sex, age (<35, 35–49, 50 years),
race (White, Black, other or unknown), geographical origin
(North America, Western Europe, sub-Saharan Africa, other
or unknown), mode of acquisition (heterosexual, homosex-
ual/bisexual, injection drug use, other or unknown), CD4
cell count (<200, 200–499, 500 cells/mm3), HIV RNA
(400, 401–1000, > 1000 copies/ml), calendar year (2002–
04, 2005–07,  2008), regimen class at initiation [non-
nucleoside (NNRTI)-based or non-NNRTI based] and regi-
men class at baseline (NNRTI-based or non-NNRTI based).
To adjust for time-varying selection bias that is induced
by the censoring required for the per-protocol analysis, we
use inverse-probability weighting to eliminate the depend-
ence between measured time-varying prognostic factors
and censoring. Informally, an uncensored individual’s
weight at time t is inversely proportional to his/her prob-
ability of remaining uncensored through time t conditional
on having survived to time t (Dt), his/her covariate history
(Lt), and his/her switching history (At1), where At¼ 2 in-
dicates that the individual has switched to an eligible regi-
men, At¼1 indicates that the individual has changed to an
ineligible regimen, and At¼ 0 indicates that the individual
has not changed treatment by week t. We weight each indi-
vidual by the time-varying inverse-probability weight: Wt
¼Qtk¼0 1f ðAkjAk1;Dk¼0;LkÞ ; where f Ak j Ak1;Dk ¼ 0;Lk
 
is
the conditional probability mass function fAkjAk1;Dk¼0;Lk
ðakjak1;dk ¼ 0; lkÞ with ðakjak1; dk ¼ 0; lkÞ evaluated at
the random argument Ak j Ak1;Dk ¼ 0;Lk
 
and
A1 ¼ 0.
As previously described,21 these probabilities are esti-
mated using pooled multinomial logistic models including a
time-specific intercept (estimated via linear and quadratic
terms for t), the baseline covariates previously listed and the
time-varying covariates: CD4 cell count (restricted cubic
spline with 5 knots at 10, 200, 350, 500 and 1000 cells/
mm3), HIV-1 RNA (400, 401–1000, >1000 copies/ml),
AIDS-defining illness (when the outcome was death alone)
and time since last laboratory measurement (<4, 4–7, 8–11,
12 weeks). For an explanation of why the probability of
treatment changes can be used to estimate the probability of
remaining uncensored, please see Cain et al. 2010.11
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Under the assumptions that: (i) we measured and
successfully adjusted for all baseline and time-varying
confounders; (ii) there is positivity (i.e. no deterministic
treatment assigned given the confounders); and (iii) the
weight models are not misspecified, the above logistic
model consistently estimates the parameter of a
dynamic marginal logistic structural model:17,22–24
logit Pr Dxtþ1 ¼ 1 j Dxt ¼ 0;V
  ¼ h0t þ h1xþ h
0
2 V, where
Dxt is the counterfactual indicator that an individual would
have developed the outcome during week t under strategy
X¼ x.
To estimate per-protocol survival curves, we fit a similar
model that included a product (‘interaction’) term between
X and f(t), where f(t) is a flexible function of time (estimated
via linear and quadratic terms for t). The model’s predicted
values are then used to estimate the 3-year survival from
baseline as previously described11,19 (nonparametric estima-
tion of survival curves would result in very unstable esti-
mates). The estimated 3-year survival can be interpreted as
the survival that would have been estimated had all individ-
uals switched according to the study protocol (regardless of
the treatment they subsequently received).
The same analytical approach is then applied to the
combined endpoint of AIDS-defining illness or death.
Inverse-probability weighting may be used to adjust for
potential selection bias due to loss to follow-up25 in both
the intention-to-treat and the per-protocol analyses.
Emulating the target trial using
observational data
In the absence of a randomized clinical trial for switching,
we emulated one using observational data22 from the
Antiretroviral Therapy Cohort Collaboration (ART-CC),
the Centers for AIDS Research (CFAR) Network of
Integrated Clinical Systems (CNICS) and the HIV-
CAUSAL Collaboration. These collaborations have been
described elsewhere.26–29 The cohorts that make up these
collaborations are listed in Appendix 1 (available as
Supplementary data at IJE online). All overlaps between
and within collaborations were removed. Each cohort col-
lected data prospectively, including CD4 cell count, HIV-1
RNA (limit of detection  200 copies/ml), dates of treat-
ment initiation and treatment changes, AIDS-defining
illness and death.
We designed our analysis of the observational data to
match the eligibility criteria, the treatment strategies, and
the outcomes of the target trial as much as possible.
Eligibility criteria
We applied the same eligibility criteria as in the target trial.
Our analysis was restricted to HIV-infected persons who
initiated antiretroviral therapy after 1 January 2002 (2004
for CoRIS, 2005 for FHDH and Frankfurt when informa-
tion on their treatment interruptions became available).
Treatment strategies
We compared the same tight- and loose-control switching
strategies as in the target trial. To reduce the influence of
data errors, new drug prescriptions of duration of 14 days
or less were disregarded when determining the existence of
switching. Instead, the time was assigned to the nearest
regimen of duration longer than 14 days before the short
regimen. In sensitivity analyses, point estimates did not
vary (data not shown) for durations of 31 and 62 days,
when we assigned the disregarded time to the nearest lon-
ger regimen after the short regimen, and when we used an
alternative definition of switching (see Table 2).
Outcomes
We considered the same two outcomes as in the target
trial: all-cause mortality and a combined endpoint of
AIDS-defining illness18 or death. The date of death was
identified using a combination of national and local mor-
tality registries and clinical records as described else-
where,28 and AIDS-defining illnesses were ascertained by
the treating physicians.
Follow-up period
Follow-up started at baseline and ended at the occurrence
of the outcome, loss to follow-up (52 weeks after the most
recent laboratory measurement) or the cohort-specific
administrative end of follow-up (up to November 2012),
whichever occurred first.
Causal contrast of interest
For the reasons explained below, only the per-protocol
effect comparing the two switching strategies can be
estimated.
Analysis
We used the same pooled logistic model described for the
target trial, except that we fitted the model to an expanded
dataset constructed as follows. Because all individuals had
data consistent with both strategies at confirmed virologi-
cal failure (baseline), we created an expanded dataset that
included two replicates (clones) of each individual, and as-
signed each replicate to one of the strategies. We censored
replicates if and when their data were no longer consistent
with their assigned strategy.17 In particular, replicates were
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censored if and when the individual changed treatment too
soon (i.e. between baseline and when HIV-1 RNA first
crossed above 400 (1000) copies/ml), if and when the indi-
vidual changed to an ineligible regimen during the 90-day
grace period and at the end of the grace period if the indi-
vidual had not yet switched to an eligible regimen.
A consequence of using grace periods with cloning and
censoring is that an intention-to-treat effect cannot be esti-
mated because each individual is assigned to all strategies
at baseline. Therefore, a contrast based on baseline assign-
ment (i.e. an intention-to-treat analysis) will compare
groups with essentially identical outcomes. Analyses with a
grace period at baseline are geared towards estimating a
per-protocol effect of a target trial.
The inverse-probability weights were the same as for
the target trial except that we added a numerator11 to emu-
late uniform switching during the grace period. This
numerator equals 1mþ1j when j¼m and when 0 j<m if
the individual initiates, and 1  1mþ1j
 
when 0 j<m if
the individual does not initiate, where m is the length of
the grace period in weeks and j is the position in the grace
period such that j¼ 0 is the beginning of the grace period
and j¼m is the end of the grace period. The weights were
truncated at the 99th percentile;30 however, truncation
had little effect on the estimates (data not shown).
The inclusion of inverse-probability weights to adjust
for censoring at 52 weeks without a laboratory measure-
ment in addition to the previously described weights had
little effect on our estimates (data not shown).
All 95% confidence intervals (CIs) were estimated via a
nonparametric bootstrap with 500 samples. All analyses were
conducted with SAS 9.4 (SAS Institute, Cary, NC, USA).
Results
Of 43 803 potentially eligible individuals, 2001 met the
baseline inclusion criteria for the mortality analysis and
1641 for the AIDS or death analysis. The most common
reason for being excluded was never experiencing virologi-
cal failure after achieving virological suppression. A flow-
chart of patients for the mortality analysis is provided in
Figure 1.
Table 3 shows the baseline characteristics of the study
population for the mortality analysis. Of the 4002
Figure 1. Modified CONSORT flow diagram for the mortality analysis in the ART-CC, the CNICS and the HIV-CAUSAL Collaboration, 2002–12.
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replicates in the expanded dataset, 74% of the tight-con-
trol group and 68% of the loose-control group were cen-
sored during follow-up. In the tight-control group, 11%
were censored for changing treatment prematurely, 14%
were censored for changing to an ineligible regimen during
the grace period and 75% were censored for not having
switched to an eligible regimen by the end of the grace
period. In the loose-control group, the respective numbers
were 23%, 14% and 63%. Among the uncensored, the me-
dian [interquartile range (IQR)] follow-up time was 89
(38, 168) weeks for the tight-control group (1673 person-
years) and 82 (40, 166) weeks for the loose-control group
(2009 person-years). The numbers were similar in the
AIDS or death analysis.
There were 21 deaths and 33 AIDS or death events in
the tight-control group, and 28 deaths and 41 AIDS or
death events in the loose-control group (Table 4; see
Appendix 2 for details, available as Supplementary data at
IJE online). Among those who died, the median (IQR)
time to death was 31 (11, 52) weeks for the tight-control
Table 3. Characteristics of 2001 HIV-infected individuals in the mortality analysis at baseline in the ART-CC, the CNICS and the
HIV-CAUSAL Collaboration, 2002–12
Characteristic No. of individuals (%)
Western Europe North America
1503 498
Sex Male 959 (63.8) 418 (83.9)
Female 544 (36.2) 80 (16.1)
Age, years < 35 540 (35.9) 92 (18.5)
35–50 774 (51.5) 278 (55.8)
> 50 189 (12.6) 128 (25.7)
Geographical Origin North America 0 (0.0) 498 (100.0)
Western Europe 587 (39.1) 0 (0.0)
Sub-Saharan Africa 516 (34.3) 0 (0.0)
Other/unknown 400 (26.6) 0 (0.0)
Race White 509 (33.9) 176 (35.3)
Black 398 (26.5) 215 (43.2)
Other/unknown 596 (39.7) 107 (21.5)
Acquisition group Heterosexual 836 (55.6) 102 (20.5)
Homosexual 482 (32.1) 158 (31.7)
Injection drug use 97 (6.5) 81 (16.3)
Other/unknowna 88 (5.9) 157 (31.5)
CD4 cell count, per mm3 < 200 387 (25.7) 150 (30.1)
200–499 801 (53.3) 250 (50.2)
 500 315 (21.0) 98 (19.7)
HIV-1 RNA, copies/ml  400 317 (21.1) 147 (29.5)
401–1000 270 (18.0) 95 (19.1)
>1000 916 (60.9) 256 (51.4)
Calendar year 2002–04 256 (17.0) 157 (31.5)
2005–07 714 (47.5) 226 (45.4)
 2008 533 (35.5) 115 (23.1)
Regimen class at initiation PIþ2 NRTI 8 (0.5) 9 (1.8)
bPIþ2 NRTI 703 (46.8) 219 (44.0)
NNRTIþ2 NRTI 785 (52.2) 268 (53.8)
< 6 drugs including FI/INSTI
(þ entry inhibitors)
7 (0.5) 2 (0.4)
Regimen class at baseline PIþ2 NRTI 15 (1.0) 10 (2.0)
bPIþ2 NRTI 732 (48.7) 229 (46.0)
NNRTIþ2 NRTI 747 (49.7) 257 (51.6)
< 6 drugs including FI/INSTI
(þ entry inhibitors)
9 (0.6) 2 (0.4)
HIV, human immunodeficiency virus; PI, protease inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; bPI, boosted protease inhibitor; NNRTI, nonnu-
cleoside reverse transcriptase inhibitor; FI, fusion inhibitor; INSTI, integrase strand transfer inhibitor.
aOther/unknown acquisition group included all VACS-VC participants.
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group and 42 (14, 113) weeks for the loose-control group.
Among those who developed AIDS or died, the median
(IQR) time to AIDS or death was 11 (2, 29) weeks for
the tight-control group and 15 (7, 60) weeks for the loose-
control group. Compared with tight control, the fully-
adjusted hazard ratios (95% CI) for loose control were
1.10 (0.73, 1.66) for death and 1.04 (0.86, 1.27) for AIDS
or death. Adjustment for either baseline or time-varying
variables did not materially change the hazard ratio esti-
mates (Table 4). The estimated inverse-probability weights
had mean 3.1 (interquartile range 1.2, 3.2, 99th percentile
15.5) for the mortality analysis, and 3.1 (interquartile range
1.1  3.4, 99th percentile 17.2) for the AIDS or death analy-
sis. The main predictors of switching were HIV-1 RNA and
time since last laboratory measurement (see Appendix
Table 1, available as Supplementary data at IJE online).
Figure 2 plots the estimated 3-year survival and 3-year
AIDS-free survival. The survival at 3 years was 95.7%
(93.4%, 98.1%) for tight control and 95.2% (92.8%,
97.6%) for loose control. The 3-year survival difference
was 0.5% (2.3%, 1.2%). The AIDS-free survival pro-
portion was 93.3% (90.5%, 96.1%) for tight control and
92.8% (89.7%, 95.9%) for loose control. The 3-year
AIDS-free survival difference was 0.5% (1.9%, 0.8%).
As a sensitivity analysis, we also considered an alterna-
tive trial in which we did not require confirmation of viro-
logical failure. In this case, baseline becomes the time of
first virological failure (defined as one measurement of
HIV-1 RNA> 200 copies/ml) following virological sup-
pression. Estimated hazard ratios using this definition of
baseline were similar (see Appendix 3 for details, available
as Supplementary data at IJE online).
Table 4. Hazard ratios of clinical outcomes under tight- and loose-control switching strategies in the ART-CC, the CNICS and the
HIV-CAUSAL Collaboration, 2002–12
Outcome Strategy
(HIV-1 RNA
threshold in copies/ml)
No. of outcomes
(overlap with tight)
Median (IQR)
time to event
in weeks
Hazard ratio, 95% confidence interval
Unadjusted Baseline-adjusted Baseline and time-
varying adjusteda,b
Death Tight (400) 21 31 (11, 52) 1 (ref.) 1 (ref.) 1 (ref.)
Loose (1000) 28 (20) 42 (14, 113) 1.11 0.88, 1.41 1.13 0.93, 1.38 1.10 0.73, 1.66
AIDS or
death
Tight (400) 33 11 (2, 29) 1 (ref.) 1 (ref.) 1 (ref.)
Loose (1000) 41 (31) 15 (7, 60) 1.08 0.90, 1.28 1.05 0.90, 1.23 1.04 0.86, 1.27
HIV, human immunodeficiency virus; IQR, interquartile range; ref., reference.
aAdjusted for the baseline covariates (sex, age, race, geographical origin, mode of acquisition, CD4 cell count, HIV RNA, calendar year, regimen class at initi-
ation, and regimen class at baseline and time-varying covariates (CD4 cell count, HIV RNA, AIDS-defining illness and time since last laboratory measurement).
bTime-varying adjustment carried out by inverse-probability weighting with weights truncated at the 99th percentile.
Figure 2 Survival (left) and AIDS-free survival (right) under tight- and loose-control switching strategies in the ART-CC, the CNICS and the HIV-
CAUSAL Collaboration, 2002–12. The curves are standardized by the baseline covariates and inverse-probability weighted by the time-varying covari-
ates listed under Table 4.
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Discussion
We have described how to use observational data to emu-
late a target trial that compares different treatment switch-
ing strategies. As an illustration, we applied the method to
the question of when to switch from a first-line antiretro-
viral regimen to a new regimen, following virological
failure.
Our results suggest that there is little difference between
switching within 90 days of HIV-1 RNA crossing above a
threshold of either 400 copies/ml or 1000 copies/ml in
terms of preventing short-term death and AIDS-defining
illness. However, even after pooling data from three large
consortia of HIV cohorts, our effective sample size was
small and the effect estimates imprecisely estimated. This
was due, in large part, to the strict eligibility criteria of our
target trial, which were defined by a panel of clinicians on
the basis of the treatment guidelines. Of the 43 803 poten-
tially eligible individuals, 95% were excluded because they
did not meet the baseline inclusion criteria. Most individ-
uals excluded were doing well on their first-line antiretro-
viral regimen and did not experience virological failure.
Had we been able to observe individuals for longer periods
of time, more of them would likely have experienced viro-
logical failure and could have been included in our
analyses.
Most individuals in our analyses contributed to both
arms of the target trial. Because one cannot generally ob-
serve the exact moment at which HIV-1 RNA thresholds
were crossed, 59% of individuals crossed both thresholds at
baseline (those with baseline HIV-RNA400 copies/ml
had the potential to cross both thresholds simultaneously
later in their follow-up). In the main analysis, 20 of 29 indi-
viduals who died and 31 of 43 individuals who developed
AIDS or died contributed events to both groups (see
Appendix 2 for details). Similar difficulties have been en-
countered when trying to emulate target trials that compare
two dynamic strategies in cancer patients.31
The validity of our methodology relies on two key
assumptions in addition to positivity. First, we assume
there is no unmeasured confounding given the measured
covariates, i.e. that all joint predictors of switching and the
outcome were included in the estimation of the inverse-
probability weights. The assumption might not hold, even
approximately, if for example previous adherence to treat-
ment and antiretroviral drug resistance remained import-
ant predictors of treatment switching and the outcome,
even after adjustment for the measured covariates (some of
which may be viewed as proxies for adherence and resist-
ance). To further protect our estimates from unmeasured
confounding, we defined the dynamic treatment strategies
in terms of initial switching regardless of subsequent
adherence to treatment. Defining the strategies this way
makes it unnecessary to adjust for joint determinants of
future switching and is perhaps more clinically meaningful,
as at the time of deciding whether or not to switch, future
adherence is unknown.
Second, we assumed a correct specification of the model
for switching as a function of the measured confounders.
To reduce bias due to model misspecification that results
in apparent outliers, we truncated the estimated weights at
the 99th percentile of the distribution of the estimated
weights.30
Our analyses only focused on the decision to switch
regimens after treatment failure, but in practice switching
may occur for other reasons, including regimen simplifica-
tion, toxicity management and avoidance of teratogenic
effects during pregnancy. The dates of pregnancies were
not available for the majority of individuals in this ana-
lysis, and we restricted the analysis to those who became
virologically suppressed and therefore were more likely
to adhere and less likely to experience treatment-related
toxicities (more common in the early stages of therapy).
We defined our treatment strategies for switching based
on HIV-1 RNA viral load only. The majority of clinical
guidelines1–4 also recommend investigating the reasons for
failure, addressing any adherence issues and performing
resistance testing while the individual is on the failing regi-
men before switching. Data on adherence and the results
of resistance testing were not available for the majority of
individuals in this analysis, but we hope to be able to
incorporate these data in the future. These considerations
may suggest that even with reasonable eligibility criteria
and minimal unmeasured confounding, our target trial was
of limited clinical relevance in the populations and periods
during which the observational data for our study were
collected.
In summary, we described an approach to compare
dynamic strategies of treatment switching via censoring
and inverse-probability weighting. We expect that the
methodological approach described here for the compari-
son of dynamic switching strategies using observational
data will serve as an example for future analyses. Future
applications may consider switching strategies for which
more HIV-infected individuals are eligible and the use of
alternative methods for comparing dynamic strategies of
treatment switching, including the parametric g-formula,
which may result in more precise estimates at the expense
of additional modelling assumptions.16,32–34
Supplementary Data
Supplementary data are available at IJE online.
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The recent paper by Cain et al.1 deals with the important
practical question of when to switch antiretroviral therapy
for HIV-infected individuals after virological failure.
However, the real significance of the paper is in advocat-
ing, and demonstrating the feasibility of, what we
may want to adopt as a general principle: analysing
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